Interferon-alpha-2b gene therapy

Drug Profile

Interferon-alpha-2b gene therapy

Alternative Names: GeneDrug™ - interferon-alpha-2b

Latest Information Update: 12 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Immune Response Corporation; Schering-Plough
  • Class
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis B; Hepatitis C

Most Recent Events

  • 12 Oct 2006 No development reported - Preclinical for Hepatitis B in USA (unspecified route)
  • 12 Oct 2006 No development reported - Preclinical for Hepatitis C in USA (unspecified route)
  • 25 Jun 2002 This product is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top